Loncastuximab tesirine
[1][2] The humanized monoclonal antibody is stochastically conjugated via a valine-alanine cleavable, maleimide linker to a cytotoxic (anticancer) pyrrolobenzodiazepine (PBD) dimer.[medical citation needed] The antibody binds to CD19, a protein which is highly expressed on the surface of B-cell hematological tumors[6] including certain forms of lymphomas and leukemias.[4] Loncastuximab tesirine treatment was continued until either disease worsened or participants experienced unacceptable side effects (toxicity).[4] Loncastuximab tesirine was granted orphan drug designation by the FDA for the treatment of diffuse large B-cell lymphoma.[9] The applicant for this medicinal product is ADC Therapeutics (NL) B.V.[9] Loncastuximab tesirine was approved for medical use in the European Union in December 2022.